Humanized Mice Model Market Expected to Witness Significant Growth, Reaching US$ 182.0 Million by 2034 with a 6.0% CAGR | Fact.MR Report
30. Januar 2025 07:00 ET
|
FACT.MR
Rockville, MD, Jan. 30, 2025 (GLOBE NEWSWIRE) -- The humanized mice model market is estimated to be US$ 101.6 million in 2024. The market is projected to expand at a CAGR of 6.0%, reaching a...
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
23. Januar 2025 07:00 ET
|
SAB Biotherapeutics, Inc.
SAB to host webinar event to discuss Phase 1 clinical trial topline results
Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025
21. Januar 2025 09:15 ET
|
Dogwood Therapeutics, Inc.
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid,...
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
13. November 2024 09:00 ET
|
INmune Bio, Inc.
Boca Raton, Florida, Nov. 13, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that...
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
27. Juni 2024 08:00 ET
|
INmune Bio, Inc.
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint. The interim analysis, performed by a third-party,...
Frontier Science Scotland Strengthens Board of Trustees with New Appointment
17. Juni 2024 04:00 ET
|
Frontier Science Scotland
KINCRAIG, Scotland, June 17, 2024 (GLOBE NEWSWIRE) -- Frontier Science Scotland (FSS), a leading contract clinical research organisation, advancing drug development by delivering excellence in...
CenExel Highlights High Level of Psychometric Rater Stress and Burnout
29. Mai 2024 13:00 ET
|
CenExel Clinical Research
Salt Lake City, Utah, May 29, 2024 (GLOBE NEWSWIRE) -- Poster presented today at American Society of Clinical Pharmacology (ASCP) Annual Meeting in Miami Beach, Florida, shows: High levels of...
INmune Bio Inc. Presents Preclinical Data at SITC 2023 Showing INB03 is an Innate Immune Check Point Inhibitor that Downregulates SIRPα
30. Oktober 2023 09:07 ET
|
INmune Bio, Inc.
SIRP-CD47 is an innate immune checkpoint known as the “don’t eat me” signal. INB03 downregulates expression of SIRPα on macrophages promote increased cancer cell death by antibody dependent cellular...
Purple Biotech Reports Potential Biomarker Data Support CM24’s Mechanism of Action
06. Oktober 2023 07:50 ET
|
Purple Biotech Ltd.
REHOVOT, Israel, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that...
Purple Biotech Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
03. Oktober 2023 07:50 ET
|
Purple Biotech Ltd.
Anti-tumor activity noted in the highest dose cohort of NT219 in combination with cetuximab; 2 out of 4 SCCHN patients at the highest dose cohort demonstrated a confirmed partial responseNT219...